- Home
- LYB vs PODD Comparison
LYB vs PODD Comparison
Compare LYB & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYB
- PODD
- Stock Information
- Founded
- LYB 1955
- PODD 2000
- Country
- LYB United States
- PODD United States
- Employees
- LYB N/A
- PODD N/A
- Industry
- LYB Major Chemicals
- PODD Medical/Dental Instruments
- Sector
- LYB Industrials
- PODD Health Care
- Exchange
- LYB Nasdaq
- PODD Nasdaq
- Market Cap
- LYB 20.3B
- PODD 23.8B
- IPO Year
- LYB N/A
- PODD 2007
- Fundamental
- Price
- LYB $48.96
- PODD $307.70
- Analyst Decision
- LYB Hold
- PODD Strong Buy
- Analyst Count
- LYB 15
- PODD 18
- Target Price
- LYB $64.67
- PODD $337.06
- AVG Volume (30 Days)
- LYB 5.1M
- PODD 687.9K
- Earning Date
- LYB 10-31-2025
- PODD 11-06-2025
- Dividend Yield
- LYB 11.08%
- PODD N/A
- EPS Growth
- LYB N/A
- PODD N/A
- EPS
- LYB 0.77
- PODD 3.32
- Revenue
- LYB $38,655,000,000.00
- PODD $2,359,500,000.00
- Revenue This Year
- LYB N/A
- PODD $29.13
- Revenue Next Year
- LYB $0.30
- PODD $18.13
- P/E Ratio
- LYB $106.86
- PODD $93.03
- Revenue Growth
- LYB 2.98
- PODD 26.00
- 52 Week Low
- LYB $47.55
- PODD $225.37
- 52 Week High
- LYB $96.81
- PODD $353.50
- Technical
- Relative Strength Index (RSI)
- LYB 36.16
- PODD 37.07
- Support Level
- LYB $48.07
- PODD $288.02
- Resistance Level
- LYB $50.05
- PODD $316.59
- Average True Range (ATR)
- LYB 1.40
- PODD 10.73
- MACD
- LYB -0.12
- PODD -3.19
- Stochastic Oscillator
- LYB 11.48
- PODD 39.99
About LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.